Lack of disease control remains a major barrier to transplant for older patients with AML.
作者信息
Jeng Mark Y, Kong Denice, Rajalingam Raja, Lin Richard J, Olin Rebecca L
机构信息
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Immunogenetics and Transplantation Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
出版信息
Bone Marrow Transplant. 2023 Sep;58(9):1054-1056. doi: 10.1038/s41409-023-02022-3. Epub 2023 Jun 23.
Abstract
摘要
相似文献
1
Lack of disease control remains a major barrier to transplant for older patients with AML.
Bone Marrow Transplant. 2023 Sep;58(9):1054-1056. doi: 10.1038/s41409-023-02022-3. Epub 2023 Jun 23.
2
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia.
Best Pract Res Clin Haematol. 2021 Dec;34(4):101320. doi: 10.1016/j.beha.2021.101320. Epub 2021 Oct 22.
3
Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia.
Best Pract Res Clin Haematol. 2017 Dec;30(4):320-326. doi: 10.1016/j.beha.2017.09.004. Epub 2017 Sep 22.
4
Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Biol Blood Marrow Transplant. 2017 Oct;23(10):1736-1743. doi: 10.1016/j.bbmt.2017.06.019. Epub 2017 Jul 5.
5
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
6
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.
7
Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.
Best Pract Res Clin Haematol. 2016 Dec;29(4):365-371. doi: 10.1016/j.beha.2016.10.012. Epub 2016 Oct 19.
8
Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Curr Hematol Malig Rep. 2013 Jun;8(2):132-40. doi: 10.1007/s11899-013-0153-6.
9
[Hematopoietic stem cell transplantation for acute myeloid leukemia].
Rinsho Ketsueki. 2016;57(10):1928-1933. doi: 10.11406/rinketsu.57.1928.
10
Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Leuk Lymphoma. 2016;57(1):76-80. doi: 10.3109/10428194.2015.1063148.
引用本文的文献
1
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Acta Haematol. 2024;147(2):133-146. doi: 10.1159/000535463. Epub 2023 Nov 30.
本文引用的文献
1
Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia.
J Geriatr Oncol. 2023 Jan;14(1):101403. doi: 10.1016/j.jgo.2022.11.002. Epub 2022 Nov 10.
2
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.
Blood Adv. 2022 Aug 9;6(15):4570-4580. doi: 10.1182/bloodadvances.2022007168.
3
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.
Bone Marrow Transplant. 2022 Jun;57(6):911-917. doi: 10.1038/s41409-022-01650-5. Epub 2022 Apr 2.
4
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
J Clin Oncol. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15.
5
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20.
6
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.
Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.
7
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns.
Blood. 2011 Feb 24;117(8):2307-18. doi: 10.1182/blood-2010-10-265603. Epub 2010 Nov 22.
8
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
J Clin Oncol. 2010 Apr 10;28(11):1878-87. doi: 10.1200/JCO.2009.25.4821. Epub 2010 Mar 8.
9
Access to hematopoietic cell transplantation in the United States.
Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5. doi: 10.1016/j.bbmt.2009.12.529. Epub 2009 Dec 28.
10
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.
Blood. 2007 Dec 15;110(13):4576-83. doi: 10.1182/blood-2007-06-097386. Epub 2007 Sep 4.
Zotero 插件